Home Overview Press Room Blog Publications For Students about us

About Assisted Reproduction

Most assisted reproductive technologies (ART) are used to treat infertility. Others are used when there are no fertility problems. Embryo screening or pre-implantation genetic diagnosis, for example, is used in order to prevent the births of children with specific genetic characteristics.

In vitro fertilization (IVF) refers to assisted reproduction procedures in which sperm and eggs are joined outside a woman's body. Women undergoing IVF are given hormonal drugs to promote the development of multiple eggs, which are retrieved with a minor surgical procedure. The eggs are mixed with sperm; one or more of those that fertilize are then transferred to the woman's uterus.

IVF has been in use since 1978 and has resulted in almost four million births worldwide. A number of IVF-related techniques have been introduced since then. Some of these, such as pre-implantation genetic diagnosis and commercial gestational surrogacy, raise significant ethical and policy concerns. In the United States alone, the assisted reproduction business is estimated to create over $3 billion in revenues a year.

Research on the risks associated with ART is notoriously inadequate. There have been few follow-up studies either on women who have used ARTs or their children. The United States is also known for having few laws governing assisted reproduction and little oversight of ART facilities.

Just What We Need: Slicker Infertility Marketingby Gina Maranto, Biopolitical Times guest contributorOctober 21st, 2016A serial tech entrepreneur launches a new start-up called Prelude with a hipster-chic website downplaying the many unknowns of egg freezing.
Reports of ‘three-parent babies’ multiplyby Sara ReardonNature NewsOctober 19th, 2016Claims of infants created using mitochondrial manipulation techniques in Mexico and China, and two pregnancies in the Ukraine, stir scientific and ethical debate.
7 Highlights from Nuffield Council’s Review on the Ethics of Genome Editingby Jessica Cussins, Biopolitical Times guest contributorOctober 18th, 2016A recent UK report discusses social and political implications of genetically engineering human reproduction and other controversial CRISPR applications.
The Misleading Promise of I.V.F. for Women Over 40by Jane E. BrodyNew York TimesOctober 17th, 2016Miriam Zoll pushes back on the optimistic picture that the fertility industry paints for consumers that masks over 20 million failed IVF cycles.
Meet Prelude Fertility, The $200 Million Startup That Wants To Stop The Biological Clock[citing CGS' Marcy Darnovsky]by Miguel HelftForbesOctober 17th, 2016Despite short and long-term risks with egg retrieval, fertility companies target young people as a new demographic, putting profits ahead of safety.
Mouse eggs made from skin cells in a dishby David CyranoskiNatureOctober 17th, 2016Research breakthrough sparks debate over the prospect of using stem cell techniques to produce synthetic human eggs from body tissue.
Three-person baby 'race' dangerous[citing CGS' Marcy Darnovsky]by James GallagherBBCOctober 12th, 2016Scientists and ethicists warn of fertility doctors forum-shopping to perform dangerous mitochondrial manipulation experiments.
Some I.V.F. Experts Discourage Multiple Birthsby Jane E. BrodyNew York TimesOctober 10th, 2016The first IVF baby was the only embryo transferred. Since then, fertility protocols have shifted in favor of more cycles and more drugs, contrary to medical evidence.
Comment on "3-person IVF" procedures for infertility reportedly conducted in UkraineOctober 10th, 2016“These developments are another urgent sign that we need clear rules placing heritable human genetic modification off-limits on a national and international level.”
3-Person IVF Breaking News: Where Are the Advocates for the Public Interest? by Leah LowthorpOctober 7th, 2016A baby created via 3-person IVF was delivered by US doctors in Mexico in order to avoid regulation. How has the media responded in the US and internationally?
Displaying 1-10 of 1520  
Next >> 
Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760